ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,741.97
-0.24%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. OKYO Pharma Ltd (OKYO)

  7. OKYO Pharma Ltd (OKYO) Noticias

OKYO OKYO Pharma Ltd

1.52
-0.025 (-1.62%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
OKYO Pharma Ltd OKYO NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.025 -1.62% 1.52 23:00:09
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.59 1.52 1.59 1.52 1.545
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
30/4/202406:00GLOBEOKYO Pharma Announces Upcoming Presentation of OK-101 Phase..
08/4/202418:00GLOBEOKYO Pharma to Reschedule Key Opinion Leader Event in Dry..
02/4/202406:00GLOBEOKYO Pharma Announces Upcoming Presentation of OK-101 Phase..
22/3/202406:00GLOBEOKYO Pharma Announces OK-101 Successfully Achieved..
21/3/202406:00GLOBEOKYO Pharma to Host Key Opinion Leader Event to Discuss New..
20/3/202406:00GLOBEOKYO Pharma to Release New and Comprehensive Data from Phase..
09/2/202406:36IHNWOKYO Pharma Receives FDA Approval of IND for OK-101 in..
09/2/202406:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/2/202406:00GLOBEOKYO Pharma Receives FDA Approval of IND for OK-101 in..
31/1/202406:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/1/202406:00GLOBEOKYO Pharma Announces Distinguished Ophthalmologists with..
08/1/202406:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202406:00GLOBEOKYO Pharma Announces OK-101 Successfully Achieved..
05/1/202408:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/1/202408:30GLOBEOKYO Pharma to Present at the Biotech Showcase Conference in..
21/12/202306:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202316:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18/12/202315:56EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202306:00GLOBEOKYO Pharma Announces Last Patient Enrolled in OK-101 Phase..
29/11/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202315:55EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202315:59EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
31/10/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202306:00GLOBEOKYO Pharma Announces $5.84 Million Cash Raise and Payables..
10/10/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/10/202310:34IHNWOKYO Pharma Announces Filing of an Investigational New Drug..
09/10/202306:00GLOBEOKYO Pharma Announces Filing of an Investigational New Drug..
05/10/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/10/202306:00GLOBEOKYO Pharma Announces Positive Safety Data Profile for the..
15/9/202315:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/9/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/9/202306:00GLOBEOKYO Pharma Announces Closing of $4.0 Million Registered..
15/9/202305:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/9/202309:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/9/202309:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/9/202308:15GLOBEOKYO Pharma Announces Pricing of $4.0 Million Registered..
14/9/202307:45GLOBEOKYO Pharma Limited Announces Withdrawal of Public Offering
13/9/202315:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/9/202315:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/9/202315:05GLOBEOKYO Pharma Announces Public Offering of Ordinary Shares
08/9/202306:04IHNWOKYO Pharma Completes Enrollment in Phase 2 Clinical Trial..
08/9/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/9/202306:00GLOBEOKYO Pharma Completes Enrollment in Phase 2 Clinical Trial..
30/8/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/8/202306:00GLOBEOKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2..
29/8/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/8/202306:00GLOBEOKYO Pharma Limited Regains Compliance with Nasdaq Listing..
25/8/202310:33EDGAR2Form 20-F/A - Annual and transition report of foreign..
15/8/202308:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..

Su Consulta Reciente

NASDAQ
OKYO
OKYO Pharma
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados